arrow
M

Mauro Cancian

university hospital of padua
H指数:23
被引数:2,085

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sustained Effectiveness of Lanadelumab in Preventing Hereditary Angioedema Attacks: The ENABLE Study

兰扎鲁玛在预防遗传性血管性水肿发作中的持续有效性:ENABLE研究

2026-08-060
OA
The Neglected Older Adults in Hereditary Angioedema: Insights From the ITACA Registry

遗传性血管性水肿中常被忽视的老年人:来自ITACA登记研究的见解

2026-05-210
OAAI
International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema

遗传性血管性水肿儿童患者诊断与管理国际指南

2026-01-300
OAAI
Biconcave vertebral fractures as a possible distinctive feature of indolent systemic mastocytosis compared with primary osteoporosis

双凹椎体骨折作为惰性系统性肥大细胞增多症与原发性骨质疏松症相比的一个可能的特征性表现

2025-12-100
OAAI
Long-term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension

Sebetralstat的长期安全性与有效性:KONFIDENT-S开放标签扩展研究的期中分析

2025-08-290
OAAI
Lanadelumab’s impact on hereditary angioedema control and quality of life across disease activity subgroups: real-world evidence

Lanadelumab对遗传性血管性水肿控制及生活质量的影响:按疾病活动度亚组分析的真实世界证据

2025-08-050
OAAI
Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to <12 years: APeX-P interim results

口服伯罗特拉司他用于2至<12岁患者遗传性血管性水肿预防:APeX-P中期结果

2025-07-250
OAAI
The Impact of COVID-19 on Patients With Bradykinin-Mediated Angioedema in the ITACA Cohort

COVID-19对ITACA队列中缓激肽介导性血管性水肿患者的影响

2025-05-090
PRE
Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study
2024-10-180
OAAI
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks
2024-07-0410
PRE
The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation
2024-06-240
OAAI
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
2024-06-013
OAAI
Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study

重组人C1-inhibitor治疗遗传性血管性水肿发作的疗效和安全性: 欧洲开放标签扩展研究

2023-11-0151
PREAI